Navigation Links
Par Pharmaceutical Reports Third Quarter 2008 Results
Date:11/6/2008

Reports Adjusted EPS of $0.26

WOODCLIFF LAKE, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced results for the third quarter ended Sept 27, 2008.

Third Quarter and Nine Month Results

For the third quarter ended September 27, 2008, Par reported total revenues of $149.0 million and net income of $1.7 million, or $0.05 per diluted share. This is compared with reported revenues of $212.7 million and net income of $1.3 million, or $0.04 per diluted share, for the same period in 2007. For the nine months ended September 27, 2008, Par reported total revenues of $416.8 million and a net loss of $15.8 million, or $0.47 per diluted share. This is compared with reported revenues of $614.5 million and net income of $45.6 million, or $1.30 per diluted share, for 2007.

Third quarter 2008 reported net income included the write-off of an intangible asset and certain inventories related to the trimming of its current generic product portfolio of $5.4 million, a charge relating to a government pricing contingency of $4.6 million, a $2.5 million impairment charge on an investment due to the downturn in the financial markets, a $1.25 million development milestone payment to MonoSol Rx, and a $2.2 million gain from the sale of non-core ANDAs. Adjusting for these one-time items, net income for the third quarter 2008 was $8.8 million, or $0.26 per diluted share. By comparison, net income in the third quarter 2007 included $16.2 million of costs related to business development activities in support of Strativa Pharmaceuticals. Adjusting for this one-time item, net income for the third quarter 2007 was $11.1 million, or $0.32 per diluted share.

Third Quarter Financial Review '/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST
2. Webcast Alert: Isis Pharmaceuticals Cardiovascular Program Review
3. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets
4. Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
5. Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
6. Jazz Pharmaceuticals to Present at Investor Conferences
7. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call
9. NeoStem Signs Definitive Agreement to Acquire Controlling Interest in a Leading Chinese Pharmaceutical Company
10. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
11. Pacira Pharmaceuticals Leverages TalentManager(R) from Salary.Com(TM) to Integrate Compensation and Performance Management Processes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014. Kessler researchers have published a ... psychoeducational wellness program in people with multiple sclerosis ... mental health, perceived stress, and pain. "Development ... individuals living with MS: Description and outcomes" was ... the International Journal of MS Care ...
(Date:9/22/2014)... 22, 2014 As concerns about ... power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) in gynecological surgeries ... detailing the continued use of uterine morcellation by ... specifically discouraged these procedures. According to The Wall ... cancer risks associated with power morcellators are overblown, ...
(Date:9/22/2014)... Barbara Bronson Gray HealthDay ... It,s something every pregnant woman wonders: What can I do ... that taking iron supplements as prescribed may play a role ... spectrum disorder (ASD). The researchers found that mothers of ... iron supplements before and during pregnancy than those whose children ...
(Date:9/22/2014)... 22, 2014 In a continued effort ... Dodge Ram is launching an awareness campaign inspired by ... or #ffbBEC) aims to raise awareness and funds for ... an egg in the air and trying to catch ... and if a nominee does not complete the challenge ...
(Date:9/22/2014)... Researchers have developed a chip capable of ... the new system to test the effectiveness of ... system, called a tumor-microenvironment-on-chip (T-MOC) device, will allow ... and the barriers that prevent the targeted delivery ... University associate professor of mechanical engineering., Researchers are ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:New chip promising for tumor-targeting research 2
... be appointed for Scotland for coordinating efforts when an epidemic ... for giving his expert advice will be paid ?50,000 annually.// ... can mutate to spread rapidly among human beings. The exact ... revealed. The person appointed will dedicate himself solely to a ...
... created a non-invasive sensor that will help treat ... a patient faces respiratory distress in the emergency ... via a mask. But for some people with ... down the body's breathing reflex. , ,Spotting ...
... the US and Canada are looking to India to ... ,"Our consortium is trying to network to provide ... Remmers, a pioneer in the study of sleep disorder ... the consortium would include Christian Guilleminault, known as the ...
... the press that the drug Dasatinib has led to reduction ... , This drug is very effective in the ... previously used drug Gleevec. ,Chronic myeloid leukemia (CML) ... stage and the blast stage.,Dasatinib was tried on all these ...
... to enroll in treatment trials for lung cancer, according to ... of CANCER, the journal of the American Cancer Society.// ... a part of the chemotherapy regimen are primarily approved after ... well as researchers have stressed the need to enroll more ...
... Robarts Research Institute have found that supplementation of GSK-3 ... produce immune cells which fights against cancer cells.// Researchers ... in the treatment of Alzheimer’s and diabetes to boost ... effects. ,Cancer chemotherapy apart from being ...
Cached Medicine News:Health News:Cheap Indian devices sought to treat sleep disorder 2Health News:Wonder drug Dasatinib gives hopes to leukemia patients 2
(Date:9/22/2014)... 22, 2014  Aethlon Medical, Inc. (OTCQB: AEMD), ... address infectious disease, cancer and other life-threatening conditions, ... Agency (DARPA) has informed the Company that it ... year four of a five-year $5.9 million contract ... 2011 under DARPA,s Dialysis-Like Therapeutics (DLT) program. ...
(Date:9/22/2014)... BC , Sept. 22, 2014 /CNW/ - T-Bird ... company focused on developing premium quality medical marijuana products, ... Thunderbird Biomedical Inc. ("Thunderbird"), has signed a definitive lease ... Victoria , BC.  The facility has 28,966 square ... approximately 14,500 square feet of mezzanine space for a ...
(Date:9/22/2014)... CHICAGO, Ill. , Sept. 22, 2014 /PRNewswire/ ... data from several clinical studies evaluating potential new ... presented at the upcoming 2014 European Society of ... Madrid, Spain . Data being ... evaluating the safety and efficacy of veliparib (ABT-888), ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 2T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4
... of six analyzer models providing a range of ... include pH, PCO 2 , PO 2 , ... calcium, chloride, glucose, and lactate. Test results are ... saving design provides the smallest footprint of any ...
... The modular design of Sleepscan VISION ... as economical upgrade opportunities. Sleepscan VISION utilizes ... to the computer through a standard Ethernet ... in the computer, allowing the Sleepscan VISION ...
... first 192 channel simultaneous sampling EEG with ... routine EEG exam rooms as well as ... Optional analysis software for automatic spike ... sleep analysis. Quality Data Acquisition ,The ...
... purchase an XLTEK Mobee, you're getting an ambulatory ... the Mobee32 and the Mobee O2 can be ... traditional in-lab EEG monitoring, or in-lab sleep studies. ... for full 10/20 electrode placement. The Mobee O2 ...
Medicine Products: